News | November 01, 2024
AbbVie to acquire Aliada Therapeutics
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India has taken the lead in recognising NAFLD as a major non-communicable disease
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Quinidine Sulphate helps manage rare irregular heartbeat conditions
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Subscribe To Our Newsletter & Stay Updated
